P-43 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable Advanced non-small cell lung cancer (NSCLC) — Do XPD polymorphisms predict for sensitivity or resistance to platinum based chemotherapy
- 31 August 2003
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 41, S101-S102
- https://doi.org/10.1016/s0169-5002(03)92012-5